StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays dropped their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.76 on Friday. The business has a 50 day moving average price of $1.92 and a two-hundred day moving average price of $2.10. Cellectis has a fifty-two week low of $1.70 and a fifty-two week high of $3.77. The firm has a market cap of $97.82 million, a PE ratio of -1.35 and a beta of 3.09. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period in the previous year, the business posted ($0.31) EPS. Sell-side analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several institutional investors and hedge funds have recently made changes to their positions in CLLS. XTX Topco Ltd acquired a new position in Cellectis in the second quarter worth $29,000. First Affirmative Financial Network bought a new position in shares of Cellectis in the 3rd quarter worth about $45,000. Principal Financial Group Inc. boosted its holdings in shares of Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC grew its position in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.